Sovargen Licenses Paxalisib from Kazia for CNS Applications
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
What happened
Sovargen Co., Ltd. exclusively licensed Paxalisib from Kazia Therapeutics Limited. The company dosed the first patient in a Phase 1b/2a clinical trial evaluating Paxalisib for intractable epilepsy linked to focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC). This dosing triggers a $2 million development milestone payment to Kazia under the terms of the exclusive licensing agreement.
Why it matters
The licensing agreement allows Sovargen to develop and commercialize Paxalisib for specific central nervous system indications. This expands the drug's potential market beyond its original focus, which was oncology. The successful trial phase could unlock further development funding and future revenue streams for both companies.
Kazia Therapeutics Limited is evaluating Paxalisib in combination regimens for advanced triple negative breast cancer through a Phase 1b trial.
From prnewswire.com
Who's involved
- Needham & CompanyIndependent investment bank and asset management firm
- Leerink partnersU.S. investment bank